WCN25-288 EFFECT OF FINERENONE TREATMENT DISCONTINUATION ON KIDNEY AND CV OUTCOMES IN PATIENTS WITH CKD AND T2D: A FIDELITY SUBANALYSIS

WCN25-288 EFFECT OF FINERENONE TREATMENT DISCONTINUATION ON KIDNEY AND CV OUTCOMES IN PATIENTS WITH CKD AND T2D: A FIDELITY SUBANALYSIS

Saved in:

Bibliographic Details
Main Authors:	Stefan Anker, Bertram Pitt, Peter Rossing, Luis Ruilope, Christiane Ahlers, Youssef Farag, Marc Lambelet, Meike Brinker, Katja Rohwedder, Zihe Zheng, Gerasimos Filippatos
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924023106
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-662 EFFICACY AND SAFETY OF FINERENONE IN PATIENTS WITH NEPHRECTOMY: A FIDELITY SUBANALYSIS
by: Jair Munoz Mendoza, et al.
Published: (2025-02-01)

Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials
by: George L Bakris, et al.
Published: (2024-03-01)

Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes
by: Gerasimos Filippatos, et al.
Published: (2025-02-01)

WCN24-432 FINERENONE IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: A FIDELITY ANALYSIS
by: Ping Li, et al.
Published: (2024-04-01)

Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD
by: Masayuki Yamanouchi, et al.
Published: (2025-07-01)

Eligibility for finerenone in real-world patients with diabetes and chronic kidney disease: Insights from the FIDELITY pooled analysis
by: Alberto Esteban-Fernández, et al.
Published: (2025-06-01)

Eligibility for finerenone in real-world patients with diabetes and chronic kidney disease: Insights from the FIDELITY pooled analysis
by: Alberto Esteban-Fernández, et al.
Published: (2025-06-01)

Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study
by: Yu Li, et al.
Published: (2025-07-01)

Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study
by: Guangting Cong, et al.
Published: (2025-08-01)

Subanalysis of the AUGUSTUS trial
by: T. V. Pavlova, et al.
Published: (2020-09-01)

Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD
by: Fang Li, et al.
Published: (2025-12-01)

WCN24-933 Effectiveness and safety of Finerenone in Chinese CKD patients without diabetes mellitus: A real-world retrospective study
by: XINGZHI WANG
Published: (2024-04-01)

Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison
by: David Cherney, et al.
Published: (2024-07-01)

Effect and Safety of Finerenone in Patients with IgA Nephropathy
by: Guo Y, et al.
Published: (2025-07-01)

HORMONAL CONTRACEPTION AND MAGNESIUM DEFICIENCY: A SUBANALYSIS OF THE MAGYN STUDY
by: D. V. Blinov, et al.
Published: (2017-06-01)

Heart failure guidelines implementation: Lifting barriers using registries and networks
by: Kalliopi Keramida, et al.
Published: (2020-07-01)

Finerenone as a therapeutic option for managing chronic kidney disease (CKD) linked to type 2 diabetes (T2D) and his other potential use. A summary of current research findings
by: Cezary Kubuj, et al.
Published: (2025-07-01)

The Multiple Extended Tidal Tails of NGC 288
by: Carl J. Grillmair
Published: (2025-01-01)

Insights on Embolic Protection, Repositioning, and Stroke: A Subanalysis of the RESPOND Study
by: Julia Seeger, et al.
Published: (2020-01-01)

Vol. 63 No. 288 (2025): JNMA: Published Monthly
by: Journal of Nepal Medical Association
Published: (2025-07-01)

Characterizing Advanced Parkinson’s Disease: Romanian Subanalysis from the OBSERVE-PD Study
by: Jozsef Attila Szasz, et al.
Published: (2021-01-01)

Assessment of Long‐Term Use Versus Discontinuation of Direct Oral Anticoagulant After Catheter Ablation for Atrial Fibrillation—RYOUMA Registry Subanalysis
by: Yuka Oda, et al.
Published: (2025-05-01)

Finerenone in diabetic kidney disease: a new frontier for slowing disease progression
by: Ibrahim S. Alhomoud, et al.
Published: (2025-06-01)

The Orthopteran Genus Hippiscus.—III (Continued From Page 288)
by: Samuel H. Scudder
Published: (1892-01-01)

Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-05-01)

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry
by: Gonzalo Luis Alonso Salinas, et al.
Published: (2025-08-01)

Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess
by: Hongxuan Fan, et al.
Published: (2025-08-01)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2023-11-01)

Flow Diversion for Intracranial Aneurysms With Incorporated Branch: A Subanalysis From the SEASE International Registry
by: Mahmoud Dibas, et al.
Published: (2024-11-01)

Sex Differences in Outcomes After Tenecteplase for Minor Stroke: A Subanalysis of the TEMPO‐2 Trial
by: Amy Y. X. Yu, et al.
Published: (2025-05-01)

Fibrinogen levels and bleeding risk in adult extracorporeal cardiopulmonary resuscitation: multicenter observational study subanalysis
by: Seiya Kanou, et al.
Published: (2025-02-01)

Correction: Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-07-01)

Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2025-05-01)

Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
by: Akshyaya Pradhan, et al.
Published: (2024-12-01)

A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone
by: I. S. Khalimov, et al.
Published: (2025-01-01)

Inside CKD: Cost-Effectiveness of Multinational Screening for CKD
by: Navdeep Tangri, et al.
Published: (2025-04-01)

CHIMIA Vol. 2, Nr. 1-12 (1948), p. 1-288
by: Schweizerischer Chemiker-Verband
Published: (1948-01-01)

Stability indicating RP-HPLC method for estimation of finerenone and its related substances in new dosage form
by: Aya A. Marie, et al.
Published: (2025-06-01)

Focus on Finerenone, a Non-Steroidal MRA in Diabetic Kidney Disease. What Physicians Should Know?
by: Dwaipayan Sarathi CHAKRABORTY, et al.
Published: (2022-03-01)

Benchmarking and Fidelity Response Theory of High-Fidelity Rydberg Entangling Gates
by: Richard Bing-Shiun Tsai, et al.
Published: (2025-02-01)